PMID- 20501678
OWN - NLM
STAT- MEDLINE
DCOM- 20100824
LR  - 20111117
IS  - 1945-7197 (Electronic)
IS  - 0021-972X (Linking)
VI  - 95
IP  - 8
DP  - 2010 Aug
TI  - Impact of exogenous hyperglucagonemia on postprandial concentrations of gastric 
      inhibitory polypeptide and glucagon-like peptide-1 in humans.
PG  - 4061-5
LID - 10.1210/jc.2010-0550 [doi]
AB  - BACKGROUND: Postprandial secretion of glucagon-like peptide 1 (GLP-1) has been 
      found diminished in some patients with type 2 diabetes mellitus (T2DM) and high 
      glucagon concentrations. We examined the effects of exogenous glucagon on the 
      release of incretin hormones. PATIENTS AND METHODS: Ten patients with T2DM and 10 
      healthy controls were examined with a meal test during the iv administration of 
      glucagon 0.65 ng/kg.min and placebo. RESULTS: GLP-1 plasma concentration 
      increased after meal ingestion in both groups (P<0.0001), but postprandial GLP-1 
      plasma levels were not affected by glucagon administration. However, immediately 
      after cessation of the glucagon infusion, GLP-1 levels increased by about 2-fold 
      to levels of 51.8+/-14.6 pmol/liter in the T2DM patients and 58.9+/-20.0 
      pmol/liter in controls (P<0.05). The time courses of glucose-dependent 
      insulinotropic peptide glucose-dependent insulinotropic peptide and GLP-1 
      concentrations were not different between T2DM patients and controls during the 
      placebo experiments (P=0.33 and P=0.13, respectively). Glucose concentrations 
      were increased by glucagon administration in controls (P<0.05, respectively), but 
      insulin and C-peptide levels were not affected. Gastric emptying was slightly 
      delayed by glucagon administration in controls (P<0.05) but not in T2DM patients 
      (P=0.77). CONCLUSIONS: Exogenous glucagon does not directly inhibit incretin 
      secretion. However, a decline in circulating glucagon levels may exert a 
      permissive effect on GLP-1 release. This might contribute to the reduction in 
      GLP-1 concentrations found in some patients with T2DM.
FAU - Meier, Juris J
AU  - Meier JJ
AD  - Department of Medicine I, St. Josef-Hospital, Ruhr-University Bochum, 
      Gudrunstrasse 56, 44791 Bochum, Germany. juris.meier@rub.de
FAU - Ritter, Peter R
AU  - Ritter PR
FAU - Jacob, Alexandra
AU  - Jacob A
FAU - Menge, Bjoern A
AU  - Menge BA
FAU - Deacon, Carolyn F
AU  - Deacon CF
FAU - Schmidt, Wolfgang E
AU  - Schmidt WE
FAU - Nauck, Michael A
AU  - Nauck MA
FAU - Holst, Jens J
AU  - Holst JJ
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20100525
PL  - United States
TA  - J Clin Endocrinol Metab
JT  - The Journal of clinical endocrinology and metabolism
JID - 0375362
RN  - 0 (Blood Glucose)
RN  - 0 (C-Peptide)
RN  - 0 (Incretins)
RN  - 0 (Insulin)
RN  - 59392-49-3 (Gastric Inhibitory Polypeptide)
RN  - 89750-14-1 (Glucagon-Like Peptide 1)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Aged
MH  - Analysis of Variance
MH  - Blood Glucose
MH  - C-Peptide/blood
MH  - Diabetes Mellitus, Type 2/*blood
MH  - Female
MH  - Gastric Inhibitory Polypeptide/*blood
MH  - Glucagon/*pharmacology
MH  - Glucagon-Like Peptide 1/*blood
MH  - Humans
MH  - Incretins/blood
MH  - Insulin/blood
MH  - Male
MH  - Middle Aged
MH  - Postprandial Period/*drug effects/physiology
EDAT- 2010/05/27 06:00
MHDA- 2010/08/25 06:00
CRDT- 2010/05/27 06:00
PHST- 2010/05/27 06:00 [entrez]
PHST- 2010/05/27 06:00 [pubmed]
PHST- 2010/08/25 06:00 [medline]
AID - jc.2010-0550 [pii]
AID - 10.1210/jc.2010-0550 [doi]
PST - ppublish
SO  - J Clin Endocrinol Metab. 2010 Aug;95(8):4061-5. doi: 10.1210/jc.2010-0550. Epub 
      2010 May 25.